PAb001-ADC / Peptron, Qilu Pharma - LARVOL DELTA

Enhancing ADC efficacy through Fc-binding peptide engineered with ECM binding moiety: A versatile platform targeting various tumors and other malignancies (AACR 2025) - "In conclusion, the binding and internalization of PAb001-ADC on cancer cells could be greatly enhanced with the conjugation of FcBC17 which in turn has resulted in the dramatic improvement of the cytotoxicity mediated with PAb001-ADC, implying that the critical limitation of conventional ADCs in controlling cellular internalization may be ameliorated through our FcBP-based approach. The versatility of our approach as an ADC enhancer will be further demonstrated across various applications, not only in targeting MUC1-expressing tumors but also in treating other types of cancers and malignancies through diverse therapeutic antibody formats."

Clinical • Oncology • MUC1

Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC (PRNewswire) - “Peptron…and Qilu Pharmaceutical…announced today that the companies have entered into an exclusive licensing agreement for the manufacturing, development and commercialization of Peptron's PAb001-ADC, the antibody-drug conjugate (the ‘ADC’) product containing the anti-MUC1 monoclonal antibody PAb001 as effective of March 26, 2021. Under the terms of the agreement, Peptron grants Qilu an exclusive global right and license to develop, manufacture, sell, and commercialize PAb001-ADC for the treatment of cancers.”

Licensing / partnership • Oncology